Industry

CXL with hypo-osmolar riboflavin shows promise in thin corneas

Healio Optometry2d ago1 min read

Accelerated corneal cross-linking using hypo-osmolar riboflavin may be used to treat keratoconus in patients with thin corneas, according to a study in Journal of Refractive Surgery.Efe Koser, MD, of University of Health Sciences, Beyoglu Eye Training and Research Hospital, Istanbul, and colleagues wrote that the Dresden protocol for cross-linking excludes patients with thinner corneas.“Alternative protocols using hypo-osmolar riboflavin solution (300 mOsmol/L, without dextran) have been developed to transiently swell thin corneas above the safety threshold to address this constraint,” they

Read full article on Healio Optometry

AI Summary

Quick Take

A study published in the Journal of Refractive Surgery demonstrates that accelerated corneal cross-linking (CXL) using a hypo-osmolar riboflavin solution (300 mOsmol/L, without dextran) is an effective approach for treating keratoconus in patients with thin corneas. This modified protocol allows for the transient swelling of the cornea, enabling patients who would otherwise be excluded by the standard Dresden protocol to safely undergo the procedure.

Why It Matters

The traditional 400-micron thickness requirement for CXL often leaves patients with advanced keratoconus with few options other than corneal transplantation. By utilizing a hypo-osmolar solution to artificially increase stromal thickness during treatment, clinicians can protect the endothelium while still delivering necessary UV energy. This research supports a shift toward more inclusive CXL protocols, potentially slowing disease progression in a higher-risk patient population that has historically been underserved by standard cross-linking techniques.

Key Findings

The use of a 300 mOsmol/L hypo-osmolar riboflavin solution successfully swells thin corneas above the safety threshold required for UV irradiation.
The specific riboflavin formulation used in this protocol is dextran-free, which is essential for inducing the necessary transient corneal thickening.
Accelerated CXL with this modified solution provides a viable alternative for patients who do not meet the corneal thickness requirements of the traditional Dresden protocol.

Study Snapshot

Design

Clinical study

Population

Patients with keratoconus and thin corneas

Practice Implications

Clinicians managing keratoconus should evaluate patients with thin corneas for modified CXL protocols rather than automatically deferring to invasive surgical options. When using hypo-osmolar riboflavin, it is critical to ensure the cornea reaches the specific safety threshold before beginning accelerated UV treatment to prevent endothelial toxicity.

Who's Affected

Cornea SpecialistsRefractive SurgeonsOphthalmologistsOptometrists

Evidence StrengthModerate

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.